FrieslandCampina Domo and Glycosyn Partner For New Infant Nutrition Ingredients
11 Feb 2016 --- FrieslandCampina Domo and U.S.-based Glycosyn have signed a technology and partnership agreement to combine their expertise in developing new infant nutrition ingredients. Glycosyn, a biotechnology company which develops products based on molecules found naturally in human milk, has formed a patented technology for the production of oligosaccharides from lactose.
FrieslandCampina Domo, leading worldwide producer of a wide range of high-quality ingredients for the infant-, medical- and cell nutrition markets, will produce and introduce these new ingredients onto the global market.
Jan-Willem ter Avest, Director of Media Relations at FrieslandCampina told NutritionInsight: ”If you look into the scientific world a lot of activities are going on and clinical trials are a normal part of a process for any innovation. We are going to decide this with customers. We are really enthusiastic about this partnership and excited about this next step towards developing a new generation of infant nutrition.”
John R. Garrett, co-CEO, at Glycosyn explains: “Human Milk Oligosaccharides (HMO’s) are specialised carbohydrates which are naturally prevalent in mother’s milk. Through our expertise and know-how we have developed technologies which will complement FrieslandCampina’s extensive history and knowledge of infant nutrition ingredients, products and markets.”
FrieslandCampina Domo’s range of products consists of whey protein concentrates, demineralised whey products, galacto-oligosaccharides, lactose, hydrolysates, encapsulated nutritional oils - as well as the emerging products which are being developed from the Glycosyn partnership.
Tine Snels, Executive Director of FrieslandCampina Ingredients says: “Glycosyn helps us to take a very exciting step towards developing the next generation of infant nutrition and to strengthen our position as a market leader in infant nutrition ingredients. We are doing this to meet the growing global demand for high-quality ingredients. Our cooperation is a perfect example of co-creation. The first quantities for trials will be available in the current year.”
By Kerina Tull
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
